Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

1,886 questions in 74 reviews · Skin

current versions

No studies 542 · 28.7%Ungraded 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Oral dehydroepiandrosterone vs placebo Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral dehydroepiandrosterone vs placebo Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral dehydroepiandrosterone vs placebo Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral dehydroepiandrosterone vs placebo Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral methotrexate vs placebo Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral dehydroepiandrosterone vs placebo Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	RR 0.09 [0.01, 1.66]	1 study · 381 participants	Moderate
Oral dehydroepiandrosterone vs placebo Adverse events: minor · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	RR 10.5 [3.26, 33.75]	1 study · 381 participants	Moderate
Oral chloroquine vs placebo Primary outcome: complete clinical response · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	RR 1.57 [0.95, 2.61]	1 study · 24 participants	Low
Oral chloroquine vs placebo Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral chloroquine vs placebo Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral chloroquine vs placebo Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral chloroquine vs placebo Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral chloroquine vs placebo Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	RR 0.33 [0.01, 7.45]	1 study · 24 participants	Low
Oral chloroquine vs placebo Adverse events: minor · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral ciclosporin vs oral azathioprine Primary outcome: complete clinical response · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	RR 0.83 [0.46, 1.52]	1 study · 89 participants	Low
Oral methotrexate vs placebo Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	RR 0.77 [0.32, 1.83]	1 study · 86 participants	Moderate
Oral ciclosporin vs oral azathioprine Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral ciclosporin vs oral azathioprine Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral ciclosporin vs oral azathioprine Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral ciclosporin vs oral azathioprine Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral ciclosporin vs oral azathioprine Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	RR 0.89 [0.48, 1.65]	1 study · 89 participants	Low
Oral ciclosporin vs oral azathioprine Adverse events: minor (hirsutism) · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	RR 9.83 [1.32, 72.95]	1 study · 89 participants	Low
Oral methotrexate vs oral chloroquine Primary outcome: complete clinical response · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	RR 1.13 [0.84, 1.5]	1 study · 25 participants	Low
Oral methotrexate vs oral chloroquine Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral methotrexate vs oral chloroquine Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral methotrexate vs oral chloroquine Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral methotrexate vs placebo Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral methotrexate vs oral chloroquine Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral methotrexate vs oral chloroquine Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	RR 1.73 [0.27, 11.07]	1 study · 41 participants	Low
Oral methotrexate vs oral chloroquine Adverse events: minor · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	RR 3.9 [1.45, 10.51]	1 study · 41 participants	Low
Oral methotrexate vs placebo Secondary outcome: Dermatology quality of life measure · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral methotrexate vs placebo Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	RR 12.05 [0.69, 211.36]	1 study · 86 participants	Moderate
Oral methotrexate vs placebo Adverse events: minor · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	RR 0.68 [0.39, 1.17]	1 study · 86 participants	Moderate
Oral hydroxychloroquine vs placebo Primary outcome: complete clinical response · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Oral hydroxychloroquine vs placebo Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus Interventions for cutaneous disease in systemic lupus erythematosus (2021) · Cochrane	RR 7 [0.41, 120.16]	1 study · 20 participants	Low
Summary of Findings Table ‐ OnabotulinumtoxinA 20U vs placebo Partcipant assessment of success · glabellar lines Botulinum toxin type A for facial wrinkles (2021) · Cochrane	RR 19.45 [8.6, 43.99]	4 studies · 575 participants	Moderate
Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs placebo Duration of treatment effect · glabellar lines Botulinum toxin type A for facial wrinkles (2021) · Cochrane	no estimate extracted	1 study · 100 participants	Moderate
Summary of Findings Table ‐ IncobotulinumtoxinA 20U vs placebo Participant assessment of success by analysing scores and scales ‐ 4 weeks · glabellar lines Botulinum toxin type A for facial wrinkles (2021) · Cochrane	RR 66.57 [13.5, 328.28]	2 studies · 547 participants	Moderate
Summary of Findings Table ‐ IncobotulinumtoxinA 20U vs placebo Major adverse events · glabellar lines Botulinum toxin type A for facial wrinkles (2021) · Cochrane	no estimate extracted	2 studies · 547 participants	Moderate
Summary of Findings Table ‐ IncobotulinumtoxinA 20U vs placebo Physician assessment of success by analysing scores and scales · glabellar lines Botulinum toxin type A for facial wrinkles (2021) · Cochrane	RR 134.62 [19.05, 951.45]	2 studies · 547 participants	Moderate
Summary of Findings Table ‐ IncobotulinumtoxinA 20U vs placebo Total adverse events · glabellar lines Botulinum toxin type A for facial wrinkles (2021) · Cochrane	RR 1.17 [0.9, 1.53]	2 studies · 547 participants	Low
Summary of Findings Table ‐ IncobotulinumtoxinA 20U vs placebo Duration of treatment effect ‐ not measured · glabellar lines Botulinum toxin type A for facial wrinkles (2021) · Cochrane	no estimate extracted	NR	No studies
Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs OnabotulinumtoxinA 20U Participant assessment success by analysing scores and scales ‐ 4 weeks · glabellar lines Botulinum toxin type A for facial wrinkles (2021) · Cochrane	RR 1 [0.92, 1.08]	1 study · 388 participants	High
Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs OnabotulinumtoxinA 20U Major adverse events ‐ Any major adverse events (eyelid ptosis, eyelid sensory disorder, s · glabellar lines Botulinum toxin type A for facial wrinkles (2021) · Cochrane	OR 2.65 [0.77, 9.09]	1 study · 433 participants	Moderate
Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs OnabotulinumtoxinA 20U Physician assessment of success by analysing scores and scales ‐ 4 weeks (Validated tools, wrinkles and lines at maximum contraction) · glabellar lines Botulinum toxin type A for facial wrinkles (2021) · Cochrane	RR 1.01 [0.95, 1.06]	1 study · 388 participants	High
Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs OnabotulinumtoxinA 20U Total adverse events · glabellar lines Botulinum toxin type A for facial wrinkles (2021) · Cochrane	RR 1.02 [0.67, 1.54]	2 studies · 492 participants	Moderate
Summary of Findings Table ‐ OnabotulinumtoxinA 20U vs placebo Major adverse events · glabellar lines Botulinum toxin type A for facial wrinkles (2021) · Cochrane	OR 3.62 [1.5, 8.74]	8 studies · 1390 participants	Moderate
Summary of Findings Table ‐ AbobotulinumtoxinA 50U vs OnabotulinumtoxinA 20U Duration of treatment effect ‐ not measured · glabellar lines Botulinum toxin type A for facial wrinkles (2021) · Cochrane	no estimate extracted	NR	No studies
Summary of Findings Table ‐ IncobotulinumtoxinA 24U vs OnabotulinumtoxinA 24U Participant assessment of success by analysing scores and scales ‐ not measured · glabellar lines Botulinum toxin type A for facial wrinkles (2021) · Cochrane	no estimate extracted	NR	No studies
Summary of Findings Table ‐ IncobotulinumtoxinA 24U vs OnabotulinumtoxinA 24U Major adverse events · glabellar lines Botulinum toxin type A for facial wrinkles (2021) · Cochrane	OR 0.02 [0, 1.77]	1 study · 381 participants	Very low